Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Peripheral Nervous System Diseases 2Mucositis 2Head and Neck Neoplasms 2Vaso-Occlusive Crises 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Pain 1Gastrointestinal Neoplasms 1Esophagitis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia, Sickle Cell 1

Interventions

Fluorouracil 131Leucovorin 127Oxaliplatin 93Bevacizumab 86Irinotecan 74Capecitabine 63Cetuximab 47Folfox protocol 32Panitumumab 18regorafenib 16trifluridine tipiracil drug combination 15Drug Therapy 14Chemotherapy, Adjuvant 13IFL protocol 10Floxuridine 10Radiotherapy 9Tegafur 7Neoadjuvant Therapy 7Levoleucovorin 7Laparoscopy 7Aspirin 7pembrolizumab 6atezolizumab 6Trifluridine 6Celecoxib 6XELOX 5Mitomycin 5Colonoscopy 5tipiracil 4sintilimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Neoplasms × Glutamine × Clear all
NCT01087658 2013-06-21

GLUTOX

Sanofi

Phase 3 Completed
200 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡